Wide Ranks

MTNB

Matinas Biopharma Holdings, Inc

0.6287

Top Statistics
Market Cap 3 M Forward PE -0.2096 Revenue Growth 0.00 %
Current Ratio 6.39 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.3370 Enterprise / Revenue Price To Sales Trailing12 Months Infinity
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 14 M Total Cash Per Share 2.85 Total Debt 3 M
Total Debt To Equity 16.97 Current Ratio 6.39 Book Value Per Share 4.43
All Measures
Short Ratio 19.00 % Message Board Id finmb_243651290 Shares Short Prior Month 62660
Return On Equity -0.9759 City Bedminster Uuid 61dd6a0e-9ad0-3bcd-b1dc-4dae373fc621
Previous Close 0.6340 First Trade Date Epoch Utc 1 B Book Value 4.43
Beta 1.73 Total Debt 3 M Volume 24021
Price To Book 0.1420 Last Split Date 1 B Fifty Two Week Low 0.5000
Total Cash Per Share 2.85 Shares Short Previous Month Date 1 B Max Age 86400
Recommendation Mean 3.00 Sand P52 Week Change 0.3133 Net Income To Common -22912000
Ask 0.6598 Short Percent Of Float 0.0066 Implied Shares Outstanding 5 M
Last Fiscal Year End 1 B Trailing Peg Ratio None Average Daily Volume10 Day 127250
Average Volume10days 127250 Total Cash 14 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0249 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 0.6340 Target Low Price 0.0000
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.28 Open 0.6110
Free Cashflow -9130125 State NJ Dividend Yield 0.00 %
Return On Assets -0.5087 Time Zone Short Name EST Trailing Eps -4.74
Day Low 0.5901 Address1 1545 Route 206 South Shares Outstanding 5 M
Price Hint 4 Target High Price 0.0000 Website https://www.matinasbiopharma.com
52 Week Change -0.9401 Average Volume 211985 Forward Eps -3.00
Recommendation Key hold Compensation As Of Epoch Date 1 B Quick Ratio 598.40 %
Last Split Factor 1:50 Regular Market Day High 0.6500 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 16.97 Fifty Two Week High 21.50
Day High 0.6500 Shares Short 32365 Regular Market Open 0.6110
Industry Key biotechnology Bid 0.6187 Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0065 Operating Cashflow -17873000
Currency USD Time Zone Full Name America/New_York Market Cap 3 M
Is_nasdaq_100 False Zip 07921 Quote Type EQUITY
Industry Biotechnology Long Name Matinas BioPharma Holdings, Inc. Regular Market Day Low 0.5901
Held Percent Institutions 0.2608 Current Price 0.6287 Address2 Suite 302
Enterprise To Ebitda 0.3370 Financial Currency USD Current Ratio 6.39
Industry Disp Biotechnology Country United States Float Shares 4 M
Two Hundred Day Average 7.33 Enterprise Value -7889644 Price To Sales Trailing12 Months Infinity
Forward PE -0.2096 Regular Market Volume 24021 Ebitda -23378000
Exchange ASE
Go to Yahoo Finance Go to Seeking Alpha 
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology.

The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy.

It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium.

The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations.

Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.